Johnson & Johnson (NYSE:JNJ) Shares Purchased by DeDora Capital Inc.

DeDora Capital Inc. grew its position in Johnson & Johnson (NYSE:JNJ) by 1.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,109 shares of the company’s stock after acquiring an additional 75 shares during the quarter. DeDora Capital Inc.’s holdings in Johnson & Johnson were worth $893,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Keener Financial Planning LLC acquired a new stake in Johnson & Johnson in the 4th quarter worth about $40,000. Stiles Financial Services Inc raised its holdings in shares of Johnson & Johnson by 2.1% during the 4th quarter. Stiles Financial Services Inc now owns 18,111 shares of the company’s stock valued at $2,840,000 after buying an additional 376 shares during the period. Impax Asset Management Group plc increased its holdings in Johnson & Johnson by 7.7% during the 4th quarter. Impax Asset Management Group plc now owns 86,904 shares of the company’s stock worth $13,621,000 after purchasing an additional 6,209 shares during the last quarter. Financial Connections Group Inc. purchased a new stake in Johnson & Johnson during the 4th quarter worth approximately $348,000. Finally, Argus Investors Counsel Inc. increased its holdings in Johnson & Johnson by 0.9% during the 4th quarter. Argus Investors Counsel Inc. now owns 9,392 shares of the company’s stock worth $1,472,000 after purchasing an additional 84 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.3 %

JNJ stock traded up $0.44 during midday trading on Friday, hitting $159.53. 2,091,135 shares of the company’s stock were exchanged, compared to its average volume of 7,322,265. The company has a market cap of $383.94 billion, a PE ratio of 9.92, a price-to-earnings-growth ratio of 2.63 and a beta of 0.52. The stock’s fifty day moving average price is $152.13 and its 200-day moving average price is $153.14. Johnson & Johnson has a one year low of $143.13 and a one year high of $175.39. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. The business had revenue of $22.45 billion for the quarter, compared to the consensus estimate of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. Johnson & Johnson’s quarterly revenue was up 4.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.80 earnings per share. Research analysts predict that Johnson & Johnson will post 10.07 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.11%. The ex-dividend date of this dividend is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. HSBC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price objective for the company from $169.00 to $170.00 in a research report on Thursday, April 18th. Daiwa Capital Markets downgraded Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their target price for the company from $160.00 to $150.00 in a research note on Tuesday, July 23rd. TD Securities dropped their price objective on Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. Morgan Stanley boosted their target price on Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 18th. Finally, StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Friday. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $173.21.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.